PLK1 and neoplasm: This system can deliver the CRISPR/Cas9 to bind with target gene Polo-like kinase 1 (PLK-1), which was a prosurvival gene overexpressed in the most tumors with antiapoptosis effect, resulting the significant effects of gene silence and tumor recession.